Literature DB >> 14715821

Metabolic bone disease in human immunodeficiency virus-infected children.

Stephen Arpadi, Mary Horlick, Elizabeth Shane.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 14715821      PMCID： PMC4103416          DOI： 10.1210/jc.2003-031942

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  31 in total

1.  Bone mineral content in girls perinatally infected with HIV.

Authors:  K O O'Brien; M Razavi; R A Henderson; B Caballero; K J Ellis
Journal:  Am J Clin Nutr       Date:  2001-04       Impact factor: 7.045

2.  Infection of human fibroblasts and osteoblast-like cells with HIV-1.

Authors:  W Mellert; A Kleinschmidt; J Schmidt; H Festl; S Emler; W K Roth; V Erfle
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

3.  Familial resemblance for bone mineral mass is expressed before puberty.

Authors:  S Ferrari; R Rizzoli; D Slosman; J P Bonjour
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

4.  Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants.

Authors:  A Prentice; T J Parsons; T J Cole
Journal:  Am J Clin Nutr       Date:  1994-12       Impact factor: 7.045

5.  A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study.

Authors:  D A Bailey; H A McKay; R L Mirwald; P R Crocker; R A Faulkner
Journal:  J Bone Miner Res       Date:  1999-10       Impact factor: 6.741

6.  Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.

Authors:  A Carr; J Miller; J A Eisman; D A Cooper
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

7.  Bone metabolism in children with human immunodeficiency virus infection receiving highly active anti-retroviral therapy including a protease inhibitor.

Authors:  B M Tan; R P Nelson; M James-Yarish; P J Emmanuel; S J Schurman
Journal:  J Pediatr       Date:  2001-09       Impact factor: 4.406

8.  HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.

Authors:  Mario Cozzolino; Marcos Vidal; Maria Vittoria Arcidiacono; Pablo Tebas; Kevin E Yarasheski; Adriana S Dusso
Journal:  AIDS       Date:  2003-03-07       Impact factor: 4.177

9.  Four-year gain in bone mineral in girls with and without past forearm fractures: a DXA study. Dual energy X-ray absorptiometry.

Authors:  Ianthe E Jones; Rachael W Taylor; Sheila M Williams; Patrick J Manning; Ailsa Goulding
Journal:  J Bone Miner Res       Date:  2002-06       Impact factor: 6.741

10.  Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis.

Authors:  C J Haug; P Aukrust; E Haug; L Mørkrid; F Müller; S S Frøland
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958
View more
  6 in total

1.  Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life.

Authors:  Aylin B Unsal; Aviva S Mattingly; Sara E Jones; Julia B Purdy; James C Reynolds; Jeffrey B Kopp; Rohan Hazra; Colleen M Hadigan
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

Review 2.  Bone disease in HIV infection: a practical review and recommendations for HIV care providers.

Authors:  Grace A McComsey; Pablo Tebas; Elizabeth Shane; Michael T Yin; E Turner Overton; Jeannie S Huang; Grace M Aldrovandi; Sandra W Cardoso; Jorge L Santana; Todd T Brown
Journal:  Clin Infect Dis       Date:  2010-10-15       Impact factor: 9.079

Review 3.  Osteoporosis in children and adolescents: etiology and management.

Authors:  Giampiero Igli Baroncelli; Silvano Bertelloni; Federica Sodini; Giuseppe Saggese
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy.

Authors:  Thanyawee Puthanakit; Rachanee Saksawad; Torsak Bunupuradah; Orasi Wittawatmongkol; Thongsuai Chuanjaroen; Sasiwimol Ubolyam; Tawatchai Chaiwatanarat; Pairunyar Nakavachara; Alan Maleesatharn; Kulkanya Chokephaibulkit
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

5.  Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.

Authors:  Denise L Jacobson; Jane C Lindsey; Catherine M Gordon; Jack Moye; Dana S Hardin; Kathleen Mulligan; Grace M Aldrovandi
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

6.  Long-term virological outcome in children receiving first-line antiretroviral therapy.

Authors:  Padmapriyadarsini Chandrasekaran; Anita Shet; Ramalingam Srinivasan; G N Sanjeeva; Sudha Subramanyan; Suba Sunderesan; Karunaianantham Ramesh; Bindu Gopalan; Elumalai Suresh; Navaneethan Poornagangadevi; Luke E Hanna; Chockalingam Chandrasekar; Christine Wanke; Soumya Swaminathan
Journal:  AIDS Res Ther       Date:  2018-11-26       Impact factor: 2.250
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.